Timedora

5 Pancreatic Endocrine Disorders and Diabetes

Learn how pancreatic hormones regulate blood glucose, how diabetes and related disorders are recognized, and how nursing care addresses glucose changes and acute complications.

How pancreatic hormones regulate glucose

Pancreatic islets help regulate blood glucose through the actions of several hormones. Beta cells release , which lowers glucose by promoting its uptake and storage. Alpha cells release , which raises glucose by stimulating the liver to release glucose. Delta cells release somatostatin, which helps regulate and secretion. Loss or excess of these hormones can cause clinically important glucose disturbances.

Diabetes types and diagnosis

is a group of disorders characterized by persistent hyperglycemia due to inadequate secretion, impaired action, or both. Common symptoms include polyuria, polydipsia, fatigue, blurred vision, and unexplained weight loss.

Type 1 diabetes results from autoimmune destruction of beta cells and requires . Type 2 diabetes involves resistance and progressive loss of secretion. Diabetes can also occur secondary to pancreatic disease, certain medications, or other conditions.

Diagnostic thresholds

For nonpregnant people, diabetes is diagnosed by any of the following:

  • A1C of 6.5%6.5\% or higher.

  • Fasting plasma glucose of 126 mg/dL126\ \text{mg/dL} or higher.

  • 22-hour glucose of 200 mg/dL200\ \text{mg/dL} or higher during an oral glucose tolerance test.

  • Random plasma glucose of 200 mg/dL200\ \text{mg/dL} or higher with classic symptoms or a hyperglycemic crisis.

Without unequivocal hyperglycemia, confirm the diagnosis with a second abnormal result.

Monitoring, treatment, and ongoing care

A1C reflects average glycemia over roughly the preceding 2–32–3 months. Self-monitoring of blood glucose and continuous glucose monitoring (CGM) can show day-to-day patterns, including time spent in range and episodes of low glucose. Monitoring plans and targets should be individualized.

Ongoing care includes assessment of kidney function, blood pressure, lipids, eyes, sensation, and feet. Early recognition of complications can prevent avoidable harm.

Treatment and nursing priorities

Treatment may include nutrition and activity planning, diabetes self-management education, glucose-lowering medicines, and . Medication selection depends on diabetes type, glucose patterns, other health conditions, and the person's goals. is essential in type 1 diabetes. Basal must not be omitted, even when the person is fasting or unable to eat, unless the treating clinician directs an appropriate alternative. Prandial should be coordinated with food intake and the prescribed plan.

Nursing care includes assessing symptoms, recent glucose patterns, oral intake, hydration, medication use, and factors that can change glucose, such as infection, procedures, or glucocorticoids. Verify type, concentration, dose, route, and timing against the order and the person's meal or feeding plan. Follow institutional safeguards because is a high-alert medication.

Match glucose checks to the situation and treatment. In hospital, check before meals when the person is eating and generally every 4–64–6 hours when not eating. Check more frequently during intravenous therapy, according to protocol. For inpatient decisions, confirm CGM readings with point-of-care glucose testing as required by policy.

Teach the person to recognize and respond to high and low glucose, use monitoring devices and medicines safely, and follow an individualized plan for illness and follow-up. Inspect feet and skin, assess sensation and circulation, and promptly report wounds, infection, or new loss of sensation.

Recognizing and treating

is glucose below 70 mg/dL70\ \text{mg/dL}. Early signs may include sweating, shakiness, hunger, palpitations, or anxiety. Worsening can cause confusion, seizure, unconsciousness, or inability to self-treat.

For a conscious person who can swallow safely, give 15 g15\ \text{g} of fast-acting glucose and recheck in 1515 minutes. Repeat if glucose is still low, following the care plan or local protocol. If the person cannot swallow safely or needs assistance, do not give oral food or fluid. Use prescribed or emergency-care intravenous dextrose according to protocol and seek urgent help. Investigate the cause and revise the treatment plan as appropriate.

Hyperglycemic emergencies

involves ketone accumulation and metabolic acidosis. involves severe hyperglycemia, dehydration, and hyperosmolality, usually without substantial ketosis or acidosis. Both are emergencies.

Possible warning signs include vomiting, abdominal pain, rapid or deep breathing, marked thirst and urination, dehydration, weakness, or altered mental status. DKA can occur with glucose below the usual high levels, particularly with sodium–glucose cotransporter 2 (SGLT2) inhibitor use. A modest glucose value does not rule out DKA when symptoms and ketones suggest it.

Suspected DKA or HHS requires urgent escalation and protocol-driven care. Priorities include frequent assessment of vital signs, mental status, hydration, urine output, glucose, ketones, electrolytes, renal function, and acid–base status. Treatment is managed with fluids, , electrolyte replacement, and treatment of the precipitating cause. Potassium requires close monitoring during treatment; clinicians follow crisis protocols to correct significant hypokalemia before starting .

Diabetes associated with pancreatic disease

occurs when pancreatic disease or injury disrupts production. Causes include chronic or acute pancreatitis, pancreatic surgery or trauma, pancreatic neoplasia, and cystic fibrosis. It may be overlooked or mistaken for type 2 diabetes.

Because pancreatic damage can affect both endocrine and digestive function, assess for weight loss, malnutrition, abdominal symptoms, and signs of exocrine insufficiency as well as hyperglycemia. The recommended screening schedule is within 3–63–6 months after acute pancreatitis and annually thereafter; chronic pancreatitis warrants annual screening.

Treatment and nutrition support are individualized. Reduced counter-regulatory hormone reserve can make glucose control and prevention especially important.

Hormone-secreting pancreatic tumors

Rare pancreatic neuroendocrine tumors can produce excess hormones and distinctive syndromes. An may cause recurrent fasting , with symptoms that improve when glucose is raised. A may cause diabetes, weight loss, and a characteristic rash.

A somatostatinoma may be associated with diabetes, diarrhea or fatty stools, and gallstones. A VIPoma can cause profuse watery diarrhea and electrolyte loss. These uncommon disorders require medical evaluation.

Nursing assessment should focus on immediate risks, especially low glucose, dehydration, electrolyte disturbance, nutritional decline, and skin problems. Concerning findings should be reported promptly.